Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
30 hedge funds and large institutions have $384M invested in Sinovac Biotech, Ltd in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 30 → 30 (0)
2% less capital invested
Capital invested by funds: $394M → $384M (-$9.03M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$46.8K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$8.15K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.29K |
SVA Hedge Fund Activity: Q3 2022 in Review
30 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q3 2022, worth a combined $384M — down 2.3% from $394M a quarter earlier.
Fund positioning in SVA was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 5 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.3K. The largest seller was UBS Group, cutting an estimated $46.8K.
- 30 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $384M of Sinovac Biotech, Ltd stock for Q3 2022, down 2.3% quarter-over-quarter.
- 0 funds opened new Sinovac Biotech, Ltd positions in Q3 2022 and 0 closed out.
- The largest Sinovac Biotech, Ltd buyer in Q3 2022 was Morgan Stanley, an estimated $1.3K added.
- The largest Sinovac Biotech, Ltd seller in Q3 2022 was UBS Group, an estimated $46.8K sold.
Based on aggregated 13F filings for Q3 2022.